151 related articles for article (PubMed ID: 31668481)
1. Identifying Co-Exposure to Opiates and Gabapentin During Pregnancy.
Loudin S; Haas J; Payne M; Linz MF; Meaney-Delman D; Honein MA; Saunders A
J Pediatr; 2020 Feb; 217():196-198. PubMed ID: 31668481
[TBL] [Abstract][Full Text] [Related]
2. Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity.
Wachman EM; Warden AH; Thomas Z; Thomas-Lewis JA; Shrestha H; Nikita FNU; Shaw D; Saia K; Schiff DM
Drug Alcohol Depend; 2018 Nov; 192():45-50. PubMed ID: 30205307
[TBL] [Abstract][Full Text] [Related]
3. Public Health Surveillance of Prenatal Opioid Exposure in Mothers and Infants.
Honein MA; Boyle C; Redfield RR
Pediatrics; 2019 Mar; 143(3):. PubMed ID: 30655335
[TBL] [Abstract][Full Text] [Related]
4. Women, Infants, and Opioids.
Lowe NK
J Obstet Gynecol Neonatal Nurs; 2017; 46(5):657-659. PubMed ID: 28802558
[No Abstract] [Full Text] [Related]
5. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study.
Huybrechts KF; Bateman BT; Desai RJ; Hernandez-Diaz S; Rough K; Mogun H; Kerzner LS; Davis JM; Stover M; Bartels D; Cottral J; Patorno E
BMJ; 2017 Aug; 358():j3326. PubMed ID: 28768628
[No Abstract] [Full Text] [Related]
6. An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids.
Loudin S; Murray S; Prunty L; Davies T; Evans J; Werthammer J
J Pediatr; 2017 Feb; 181():286-288. PubMed ID: 27889067
[TBL] [Abstract][Full Text] [Related]
7. Statewide Task Force on Prescription Drug Abuse and Newborns Update: Neonatal Abstinence Syndrome Data Summary.
Fla Nurse; 2015 Jun; 63(2):14. PubMed ID: 26259378
[No Abstract] [Full Text] [Related]
8. Accuracy of diagnostic codes for prenatal opioid exposure and neonatal opioid withdrawal syndrome.
Kuzniewicz MW; Campbell CI; Li S; Walsh EM; Croen LA; Comer SD; Pimentel SD; Hedderson M; Sun LS
J Perinatol; 2023 Mar; 43(3):293-299. PubMed ID: 36131095
[TBL] [Abstract][Full Text] [Related]
9. Understanding barriers to timely identification of infants at risk of neonatal opiate withdrawal syndrome.
Howell MP; Smith AM; Lindsay EB; Drury SS
J Matern Fetal Neonatal Med; 2021 Apr; 34(7):1161-1166. PubMed ID: 31195865
[TBL] [Abstract][Full Text] [Related]
10. Time for the Finnegan Neonatal Abstinence Syndrome Scoring Tool to Be Retired?
Verklan MT
J Perinat Neonatal Nurs; 2019; 33(3):276-277. PubMed ID: 31335858
[No Abstract] [Full Text] [Related]
11. Universal maternal drug testing in a high-prevalence region of prescription opiate abuse.
Wexelblatt SL; Ward LP; Torok K; Tisdale E; Meinzen-Derr JK; Greenberg JM
J Pediatr; 2015 Mar; 166(3):582-6. PubMed ID: 25454935
[TBL] [Abstract][Full Text] [Related]
12. Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida.
Wang X; Zhu Y; Dave CV; Alrwisan AA; Voils SA; Winterstein AG
Pharmacotherapy; 2017 Jul; 37(7):806-813. PubMed ID: 28500694
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine: a new player in neonatal withdrawal syndrome.
Nanda S; Brant R; Regier M; Yossuck P
W V Med J; 2015; 111(1):16-21. PubMed ID: 25665273
[TBL] [Abstract][Full Text] [Related]
14. Maternal Substance Use and Neonatal Abstinence Syndrome: A Descriptive Study.
McQueen KA; Murphy-Oikonen J; Desaulniers L
Matern Child Health J; 2015 Aug; 19(8):1756-65. PubMed ID: 25656717
[TBL] [Abstract][Full Text] [Related]
15. Identification of Substance-Exposed Newborns and Neonatal Abstinence Syndrome Using ICD-10-CM - 15 Hospitals, Massachusetts, 2017.
Goyal S; Saunders KC; Moore CS; Fillo KT; Ko JY; Manning SE; Shapiro-Mendoza C; Gupta M; Romero L; Coy KC; McDow KB; Keaton AA; Sinatra J; Jones K; Alpren C; Barfield WD; Diop H
MMWR Morb Mortal Wkly Rep; 2020 Jul; 69(29):951-955. PubMed ID: 32701936
[TBL] [Abstract][Full Text] [Related]
16. Early Prediction Tool to Identify the Need for Pharmacotherapy in Infants at Risk of Neonatal Abstinence Syndrome.
Isemann BT; Stoeckle EC; Taleghani AA; Mueller EW
Pharmacotherapy; 2017 Jul; 37(7):840-848. PubMed ID: 28500629
[TBL] [Abstract][Full Text] [Related]
17. Implications of Tennessee's Opioid Legislation for Neonatal Abstinence Syndrome.
Shearer JN; Erwin PC; Davis SK; Anderson JG; Lindley LC
Policy Polit Nurs Pract; 2019 Aug; 20(3):153-162. PubMed ID: 31390304
[TBL] [Abstract][Full Text] [Related]
18. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.
Welle-Strand GK; Skurtveit S; Jones HE; Waal H; Bakstad B; Bjarkø L; Ravndal E
Drug Alcohol Depend; 2013 Jan; 127(1-3):200-6. PubMed ID: 22841456
[TBL] [Abstract][Full Text] [Related]
19. Neonatal Abstinence Syndrome in West Virginia Substate Regions, 2007-2013.
Stabler ME; Long DL; Chertok IR; Giacobbi PR; Pilkerton C; Lander LR
J Rural Health; 2017 Jan; 33(1):92-101. PubMed ID: 26879950
[TBL] [Abstract][Full Text] [Related]
20. Prenatal substance abuse: short- and long-term effects on the exposed fetus.
Behnke M; Smith VC; ;
Pediatrics; 2013 Mar; 131(3):e1009-24. PubMed ID: 23439891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
